NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from prospective pioglitazone clinical trial in macrovascular […]
Category Archives: Diabetes
NPC Archive Item: FDA safety warning for exenatide (Byetta▼)
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Reports from the USA of potentially fatal haemorrhagic or necrotising pancreatitis increase concerns over the safety of exenatide Action Healthcare professionals should be alert for signs or symptoms of […]
NPC Archive Item: Is aliskiren plus losartan renoprotective in patients with type 2 diabetes and nephropathy?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Parving H-H, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. NEJM 2008;358:2433-46 Aliskiren reduces the mean urinary albumin-to-creatinine ratio when added […]
NPC Archive Item: Meta-analysis of observational studies on cardiovascular effects of metformin plus sulphonylureas — no need to change practice
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Rao AD, Kuhadiya N, Reynolds K, et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of […]
NPC Archive Item: Putting blood glucose control in type 2 diabetes into perspective
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Krumholz HM, Lee TH. Redefining quality – Implications of recent clinical trials. Perspective article. New Engl J Med 2008;28:2537–9 Intensive strategies to achieve tighter blood glucose control do not […]
NPC Archive Item: Updated guidance on management of type 2 diabetes from NICE
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE Clinical Guideline 66: Type 2 diabetes: the management of type 2 diabetes (update) NICE has updated its guidance on the management of type 2 diabetes from 2002, incorporating […]
NPC Archive Item: Short-term, intensive insulin therapy for new type 2 diabetes patients?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre […]
NPC Archive Item: NPC Podcast – 12th May 2008
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Self monitoring of blood glucose: less benefit than you might think [podcast]http://www.npc.nhs.uk/podcast/NPCiPodcast_12thMay08.mp3[/podcast] Subscribe to the NPC podcast via the iTunes store Subscribe to the NPC podcast via RSS feed
NPC Archive Item: Structured education in type 2 diabetes – results of the DESMOND programme
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Davies MJ, Heller S, Skinner TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type […]
NPC Archive Item: Cases of lung cancer reported in clinical trials of inhaled insulin (Exubera®▼)
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. http://www.fda.gov/medwatch/safety/2008/safety08.htm#exubera The FDA in America has issued a Dear Healthcare Professional letter regarding cases of lung cancer in clinical trials and during post-marketing surveillance in patients treated with Pfizer’s […]